Airworks Nebulizer pe1200m
Device Facts
| Record ID | K162041 |
|---|---|
| Device Name | Airworks Nebulizer pe1200m |
| Applicant | Convexity Scientific, LLC |
| Product Code | CAF · Anesthesiology |
| Decision Date | May 2, 2017 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 868.5630 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The Airworks™ Nebulizer pe1200m, for use by adolescent and adult patients, is intended to aerosolize healthcare provider-prescribed solutions for inhalation that are approved for use with a general-purpose nebulizer. Airworks™ Nebulizer pe1200m is intended for use at home or a medical facility, such as a hospital or doctor's office.
Device Story
Airworks™ Nebulizer pe1200m is a portable, hand-held, battery-operated vibrating mesh nebulizer. Device utilizes a medical-grade stainless steel disk with 1,000 precision-formed holes; piezoelectric energy vibrates disk at ~110,000 Hz. Pressure differential across apertures draws liquid through, creating consistent aerosol droplets for inhalation via mouthpiece. Used by adolescent and adult patients at home or in medical facilities. Device is lightweight, compact, and silent; powered by rechargeable lithium-ion battery. Healthcare providers prescribe inhalation solutions; patients self-administer. Output is aerosolized medication for respiratory treatment. Benefits include portability and efficient drug delivery.
Clinical Evidence
Bench testing only. Comparative particle characterization via Cascade Impactor performed using Albuterol Sulfate, Ipratropium Bromide, and Cromolyn. Metrics included MMAD, GSD, Respirable Particle Fraction, Total Respirable Dose, Total Delivered Dose, and Respirable Drug Delivery Rate. Results demonstrate substantial equivalence in aerosol performance. Biocompatibility testing conducted per ISO 10993-1. Electrical safety and EMC testing performed per IEC 60601-1, IEC 60601-1-11, IEC 60601-1-2, and IEC 62133.
Technological Characteristics
Vibrating mesh technology; medical-grade stainless steel aperture disk. Piezoelectric energy source; 3.7 VDC rechargeable lithium-ion battery. Dimensions: 27 x 119 x 54 mm; Weight: 103 g. Reservoir capacity: 5 mL. Patient contact materials tested per ISO 10993-1. Complies with IEC 60601-1, IEC 60601-1-11, IEC 60601-1-2 (ed 4.0), and IEC 62133.
Indications for Use
Indicated for adolescent and adult patients requiring aerosolized healthcare provider-prescribed inhalation solutions approved for general-purpose nebulizers. Intended for home or medical facility use.
Regulatory Classification
Identification
A nebulizer is a device intended to spray liquids in aerosol form into gases that are delivered directly to the patient for breathing. Heated, ultrasonic, gas, venturi, and refillable nebulizers are included in this generic type of device.
Predicate Devices
- Aeroneb® Go Nebulizer (K032849)
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the circle is an abstract symbol that resembles a stylized caduceus or a series of human profiles.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
May 2, 2017
Convexity Scientific LLC % Susan Goldstein-Falk Official Correspondent mdi Consultants. Inc. 55 Northern Blvd., Suite 200 Great Neck, New York 11021
Re: K162041
Trade/Device Name: Airworks™ Nebulizer pe1200m Regulation Number: 21 CFR 868.5630 Regulation Name: Nebulizer Regulatory Class: Class II Product Code: CAF Dated: March 29, 2017 Received: March 30, 2017
Dear Ms. Goldstein-Falk:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{1}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Tina
Kiang-S
Tina Kiang, Ph.D. Acting Director Division of Anesthesiology. General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known) K162041
Device Name
Airworks™ Nebulizer pe1200m
#### Indications for Use (Describe)
The Airworks™ Nebulizer pel 200m, for use by adolescent and adult patients, is intended to aerosolize healthcare provider-prescribed solutions for inhalation that are approved for use with a general-purpose nebulizer. Airworks™ Nebulizer pe1200m is intended for use at home or a medical facility, such as a hospital or doctor's office.
Type of Use (Select one or both, as applicable)
| <span></span> <span></span> Prescription Use (Part 21 CFR 801 Subpart D) |
|--------------------------------------------------------------------------|
| <span></span> <span></span> Over-The-Counter Use (21 CFR 801 Subpart C) |
# CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
# 510(k) Summary K162041
| Convexity Scientific LLC<br>36 Church Lane<br>Westport, CT 06880 | Tel: (203) 557-6254 |
|------------------------------------------------------------------|---------------------------------------------|
| Date: | May 1, 2017 |
| Official Contact: | Paul Reiferson—President |
| Proprietary or Trade Name: | Airworks™ Nebulizer pe1200m |
| Common/Usual Name: | Nebulizer |
| Classification Name/Code: | CAF, Class 2, Nebulizer<br>CFR 868.5630 |
| Predicate Device: | Aerogen, Inc.—Aeroneb® Go Nebulizer—K032849 |
#### Device Description
The Airworks™ Nebulizer pe1200m, for use by adolescent and adult patients, is intended to aerosolize healthcare provider-prescribed solutions for inhalation that are approved for use with a general-purpose nebulizer.
The Airworks™ Nebulizer pe1200m uses a vibrating mesh technology, which is comprised of a medicalgrade stainless steel disk containing 1,000 precision-formed holes. When energy is applied, the disk vibrates approximately 110,000 times per second. This rapid vibration causes a difference in pressure on either side of each aperture, drawing liquid through the holes to form consistently sized droplets.
The Airworks™ Nebulizer pe1200m is lightweight, compact and virtually silent. A rechargeable lithiumion battery powers the device.
#### Indications for Use
The Airworks™ Nebulizer pe1200m, for use by adolescent and adult patients, is intended to aerosolize healthcare provider-prescribed solutions for inhalation that are approved for use with a general-purpose nebulizer. Airworks™ Nebulizer pe1200m is intended for use at home or a medical facility, such as a hospital or doctor's office.
{4}------------------------------------------------
# 510(k) Summary
# Comparison and Equivalence of Proposed Device and Predicate Device
| Features | Proposed Device | Predicate Device (K032849) | Substantially<br>Equivalent<br>(SE) or<br>Different |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
| Device Name | Airworks™ Nebulizer pe1200m | Aeroneb® Go nebulizer | |
| 510(k) Number | K162041 | K032849 | |
| Indications for use | The Airworks™ Nebulizer<br>pe1200m, for use by adolescent<br>and adult patients, is intended to<br>aerosolize clinician-prescribed<br>solutions for inhalation that are<br>approved for use with a general-<br>purpose nebulizer. Airworks™<br>Nebulizer pe1200m is intended for<br>use at home or a medical facility,<br>such as a hospital or doctor's<br>office. | The Aeroneb® Go nebulizer, for<br>use by pediatric and adult patients,<br>is intended to aerosolize physician-<br>prescribed solutions for inhalation<br>that are approved for use with a<br>general-purpose nebulizer. | SE |
| Target Population | Adolescent to adult | Pediatric to adult | Different |
| Mode of Operation | | | |
| Energy Source | Lithium-ion battery (rechargeable)<br>3.7 VDC, 500mA | Battery—3 "AA" disposable or<br>rechargeable batteries, 4.5 VDC,<br>350 mA | Different |
| Anatomical Site | Mouth | Mouth | SE |
| Mode of Operation | Piezoelectric/Ultrasonic | Piezoelectric/Ultrasonic | SE |
| Energy Type | Electricity | Electricity | SE |
| Nebulizing method | Vibrating mesh | Vibrating mesh | SE |
| Aerosolization Element | Aperture disk | Aperture disk | SE |
| Software-driven | No | No | SE |
| User Interface | | | |
| Patient Connector | Mouthpiece | Mouthpiece or optional mask | SE |
| Patient Interface | Hand-Held | Hand-Held | SE |
| Use | Single Patient | Single Patient | SE |
| Physical Description | | | |
| Components Cleanable | Yes | Yes | SE |
| Operating Conditions | 5°C to 40°C to 95% RH | 5°C to 45°C to 95% RH | SE |
| Storage Conditions | -10°C to 45°C to 93% RH | -20°C to 60°C to 95% RH | Different |
| Dimensions (Main Unit) | 27 x 119 x 54 mm | 40 x 105 x 95 mm | Different |
| Weight | 103 g | 325 g | Different |
| Portable | Yes | Yes | SE |
| Reservoir (mL) | 5 mL | 6 mL | Different |
{5}------------------------------------------------
510(k) Summary Page 3 of 5 May 1, 2017
#### Differences Between Proposed Device and Predicate Device
The differences between the proposed device and the predicate device are:
- Energy source: the proposed device uses a rechargeable lithium-ion battery; the predicate device uses 3 "AA" disposable or rechargeable batteries.
- Dimensions and weight: the proposed device is smaller than the predicate device. The smaller size of the proposed device's Main Unit is largely attributable to its internalized mouthpiece, which can be engaged into position when needed. The predicate device also includes a separate control module that uses 3 "AA" batteries, which adds 260 g to its weight.
- . Storage conditions: the proposed device uses an IEC 62133-certified, rechargeable lithium-ion battery whose specifications indicate storage conditions of -10℃ to +45℃. The only component affected by storage temperature is the battery. Conditions for storage and transport were taken into consideration for the selection of materials used in the subject device's construction: namely, a battery that complies with applicable consensus standards.
- Reservoir: the proposed device has a 5mL capacity reservoir; the predicate device has a 6mL capacity reservoir. The proposed device's smaller reservoir mitigates the hazard a patient could inhale two medication ampules in one sitting.
These are not significant differences that affect the safety or effectiveness of the intended device compared to the predicate device.
# Substantial Equivalence
The Airworks™ Nebulizer pe1200m is viewed as substantially equivalent to the predicate device because:
#### Indications for Use-
The indications for use are as a general-purpose nebulizer intended to aerosolize clinician-prescribed solutions for inhalation by adolescent and adult patients.
Discussion-The indications for use statements are nearly identical except for patient population. The subject device's patient population is more restrictive than the predicate device's. Since non-physician clinicians may prescribe nebulizers, we have substituted the word "clinician" above. Both devices are indicated for use as a general-purpose nebulizer.
#### Technology-
Both the proposed and the predicate device use piezoelectric energy to vibrate an element with precisely drilled holes ("vibrating mesh") to create an aerosol. The proposed device uses a different battery technology than the predicate.
Discussion-The particle characterization performance demonstrates that the two devices perform substantially equivalently. The proposed device's battery decreases its weight and, relative to disposable batteries, its long-term cost of use. The battery is IEC 62133-compliant and does not raise new safety issues.
{6}------------------------------------------------
#### 510(k) Summary
Page 4 of 5 May 1, 2017
#### Non-Clinical Testing Summary
#### Particle characterization -
Comparative particle test results via Cascade Impactor are shown below:
(All data shown at a 95% confidence level)
| Characteristic | Airworks™ Nebulizer pe1200m (K162041) | | | Predicate Device – Aeroneb Go (K032849) | | |
|-----------------------------------------------|---------------------------------------|---------------|----------------|-----------------------------------------|---------------|-----------------|
| | Albuterol | Ipratropium | Cromolyn | Albuterol | Ipratropium | Cromolyn |
| | Sulfate | Bromide | | Sulfate | Bromide | |
| | 2.5mg/3ml | 0.5mg/2ml | 4.0mg/2ml | 2.5mg/3ml | 0.5mg/2ml | 4.0mg/2ml |
| MMAD (µm) | 2.21 - 2.41 | 2.12 - 2.22 | 2.15 - 2.37 | 1.96 - 2.26 | 1.92 - 2.12 | 1.65 - 2.17 |
| GSD (µm) | 1.53 - 1.67 | 1.45 - 1.51 | 1.48 - 1.60 | 2.04 - 2.50 | 1.83 - 2.29 | 1.96 - 2.20 |
| Respirable Particle Fraction (%) | 84.2 - 91.4 | 87.4 - 93.2 | 83.5 - 92.7 | 78.8 - 83.2 | 84.0 - 91.2 | 76.7 - 86.3 |
| Total Respirable Dose (0.4 - 4.7 µm) (µg) | 851.3 - 991.9 | 194.5 - 224.3 | 773.3 - 942.1 | 818.2 - 1031.4 | 197.3 - 235.3 | 608.5 - 981.9 |
| Total Delivered Dose (µg) | 984.3 - 1093.5 | 211.6 - 250.1 | 897.0 - 1019.9 | 1012.7- 1257.0 | 221.8 - 270.5 | 758.7 - 1186.60 |
| Total Coarse Particle Dose (>4.7 µm) (µg) | 33.1 - 105.3 | 3.6 - 11.2 | 48.5 - 122.9 | 110.6 - 177.4 | 17.0- 35.6 | 66.4 - 171.8 |
| Total Fine Particle Dose (<4.7 µm) (µg) | 895.5 - 1043.9 | 207.1 - 239.7 | 791.8 - 953.6 | 891.0 - 1090.8 | 200.0 - 239.7 | 665.5 - 1041.5 |
| Total Extra-Fine Particle Dose (<1.0 µm) (µg) | 332.9 - 416.9 | 83.1 - 96.5 | 309.3 - 404.1 | 463.5 - 585.4 | 99.7 - 140.2 | 411.3 - 573.8 |
| Respirable Drug Delivery Rate (µg/min) | 133.5 - 169.1 | 24.6 - 39.0 | 147.6 - 169.2 | 143.5 - 238.5 | 34.2 - 46.4 | 133.5 - 213.7 |
#### Summary of results -
The Airworks™ Nebulizer pel 200m was found to be substantially equivalent in all performance areas having therapeutic effects except as noted below: differences in GSD and Respirable Particle Fraction only are explained by the subject device's relative outperformance of the predicate. Differences in MMAD within the desired raise new questions of safety and effectiveness. Respirable Drug Delivery Rate (inratropium only) vas slower than the predicate device; hower rate did not result in a statistically significant difference in either Respirable Particle Fraction, Total Respirable Dose, or Total Delivered Dose, the difference does not raise new questions of safety and effectiveness.
Differences in Total Coarse Particle Dose (for albuted by the subject devices relative outperformance in Total Respirable Dose. Differences in Total Extra-Fine Particle Dose do not raise new questions of safety and effectiveness.
Based on these comparative results, the subject device is substantially equivalent to the predicate device.
{7}------------------------------------------------
#### 510(k) Summary Page 5 of 5 May 1, 2017
#### Materials-
Materials in patient contact or in the gas pathway were tested in accordance with ISO 10993-1 (2009, Revised 2013) and the results satisfied the requirements. Testing included Ozone, Carbon Monoxide and Carbon Dioxide, VOC, PM25, Cytotoxicity, Sensitization, Ames Assay, Chromosomal Aberration, Mouse Lymphoma, Implantation, and Leachability and Extractability at 50°C for 72 hours with a complete Risk Assessment.
#### Non-Clinical Testing (Aerosol Performance)-
- Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators, Cleaning and Disinfection Validation, Office of Device Evaluation, Division of Cardiovascular and Respiratory Devices, October 1, 1993.
#### Cleaning and Disinfection Validation-
- AAMI / ANSI / ISO 11737-1:2006(R)2011
- ISO / TS 15883-5:2005
- AAMI TIR 12:2010
- AAMI TIR 30:2011 ●
- Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling, Guidance for Industry and Food and Drug Administration Staff, March 17, 2015.
# Electromagnetic Compatibility, Electrical Safety and Battery Testing-
The proposed device was tested to comply with the following standards, met all of the acceptance criteria of the tests and no safety or efficacy issues were discovered:
- IEC 62133 (2012)
- IEC 60601-1 (2012)
- IEC 60601-1-11 (2010) .
- . IEC 60601-1-2 tests evaluated to the requirements in ed4.0 (2014-02)
#### Substantial Equivalence Conclusion
Convexity Scientific LLC has demonstrated through the performance testing and non-clinical testing discussed above that the proposed device has been found to be substantially equivalent to the predicate. Differences between the proposed device and the predicate do not raise new questions of safety or efficacy.
